Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Centre Leon Berard
Peking University People's Hospital
M.D. Anderson Cancer Center
Eulji University Hospital
Gruppo Italiano Malattie EMatologiche dell'Adulto
Fundacion CRIS de Investigación para Vencer el Cáncer
OHSU Knight Cancer Institute
GWT-TUD GmbH
Gruppo Italiano Malattie EMatologiche dell'Adulto
Associazione Italiana Pazienti Leucemia Mieloide Cronica
Fundación Teófilo Hernando, Spain
M.D. Anderson Cancer Center
Hospices Civils de Lyon
OHSU Knight Cancer Institute